Is First Tracks Biotherapeutics Inc (TRAX) a Buy, Sell, or Hold?
NASDAQ : TRAX
First Tracks Biotherapeutics Inc
$36.13 USD
$1.76 (5.12%)
- Volume
- 474.47K
- Average Volume
- 623.25K
- Market Capitalization
- $1.26B
- P/E Ratio
- -12.86
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $38.49
- Year Low
- $14.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.74
| Source | Headline |
|---|---|
|
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: globenewswire.com - 2026-05-21 16:15:00 |
|
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
SAN DIEGO, Calif. , May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: 2026 Jefferies Global Healthcare Conference, New York Format - Presentation and one-on-one investor meetings Date and Time - Wednesday, June 3, 2026 at 12:15pm ET / 9:15am PT Leerink Partners Therapeutics Forum, Boston Format - One-on-one investor meetings Date and Time - Tuesday, July 14, 2026 A live webcast of the presentation will be available on the investor section of the First Tracks website at https://ir. globenewswire.com - 2026-05-21 16:15:00 |
|
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. globenewswire.com - 2026-05-14 16:15:00 |
|
First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away. seekingalpha.com - 2026-05-06 04:13:07 |
